Percutaneous Coronary Intervention Before TAVR: A Nationwide Synthesis of Clinical Outcomes and Bleeding Risks

Highlights

• Routine PCI prior to TAVR in patients with significant CAD showed no improvement in the primary composite outcome of all-cause mortality, MI, or urgent revascularization (HR 0.98).
• Pre-TAVR PCI was associated with a 59% increased risk of bleeding (OR 1.59), likely driven by the requirement for dual antiplatelet therapy in an elderly, comorbid population.
• The intervention successfully reduced the long-term risk of any revascularization (HR 0.46), suggesting a benefit in procedural planning but not in hard clinical endpoints.
• Instrumental variable analysis provides robust real-world evidence, suggesting that a conservative ‘Aorta-First’ approach is viable for most patients with stable coronary lesions.

Background

Coronary artery disease (CAD) is a frequent comorbidity in patients undergoing transcatheter aortic valve replacement (TAVR), with an estimated prevalence between 40% and 75%. Historically, the management of CAD in these patients was influenced by the surgical paradigm, where coronary artery bypass grafting (CABG) is routinely combined with surgical aortic valve replacement (SAVR). However, the applicability of this strategy to the TAVR population—who are typically older and have higher frailty scores—remains a subject of intense debate.

While percutaneous coronary intervention (PCI) is technically feasible before, during, or after TAVR, clinical guidelines have lacked strong evidence to mandate routine pre-procedural revascularization for stable CAD. The primary clinical concern is whether untreated coronary stenosis will exacerbate myocardial ischemia during the TAVR procedure or impair long-term survival. Conversely, the risks of PCI, including vascular complications and the mandatory use of dual antiplatelet therapy (DAPT), may outweigh the benefits in a population already at high risk for bleeding. This review synthesizes the latest nationwide evidence to clarify the role of pre-TAVR PCI.

Key Content

Methodological Innovation: The Instrumental Variable Approach

The study by Louca et al. (2026) utilized a nationwide cohort of 2,578 Swedish patients from the SWEDEHEART registry. To overcome the inherent selection biases of observational data—where healthier patients might be more likely to receive PCI, or conversely, more complex patients might receive it as a ‘protective’ measure—the researchers employed an instrumental variable (IV) analysis. By using regional and quarterly treatment preferences as the ‘instrument,’ the study simulates a natural randomization, providing a level of evidence that approaches that of a randomized controlled trial (RCT) in terms of controlling for unmeasured confounders.

Clinical Outcomes and Mortality

In the primary analysis, PCI before TAVR did not yield a significant reduction in the composite endpoint of all-cause mortality, myocardial infarction (MI), and urgent revascularization (IV-adjusted HR 0.98; 95% CI, 0.85-1.14; P=0.80). Furthermore, individual secondary outcomes, including cardiovascular mortality and stroke, showed no statistical difference between the PCI group and the conservative management group. These findings are consistent with the ACTIVATION trial, which also suggested that PCI before TAVR does not provide a safety or efficacy advantage over TAVR alone in stable patients.

The Trade-off: Revascularization vs. Bleeding

A critical finding of this synthesis is the divergent impact of PCI on future procedures versus safety. Patients who underwent PCI before TAVR had a significantly lower risk of requiring ‘any’ revascularization during follow-up (adjusted HR 0.46; 95% CI, 0.30-0.72). This indicates that while PCI effectively treats the targeted stenoses, these lesions might not have become clinically significant if left alone.

However, this reduction in future procedures came at a high cost. The PCI cohort experienced a substantially higher risk of bleeding (IV-adjusted OR 1.59; 95% CI, 1.23-2.04). In the context of TAVR, bleeding is a major predictor of mortality and poor functional recovery. The necessity of DAPT following stent implantation, often on top of oral anticoagulants required for atrial fibrillation in this demographic, creates a ‘triple therapy’ or ‘high-bleeding’ environment that clinicians must carefully navigate.

Physiological Considerations in Aortic Stenosis

The lack of benefit from pre-TAVR PCI can be partially explained by the physiological changes that occur following valve replacement. Severe aortic stenosis (AS) increases left ventricular afterload and myocardial oxygen demand while simultaneously decreasing coronary perfusion pressure. Once the stenotic valve is replaced, the immediate reduction in afterload and the improvement in diastolic perfusion often alleviate the ischemic burden caused by moderate-to-severe coronary stenoses. This ‘physiological relief’ may render many stable coronary lesions asymptomatic and clinically silent post-TAVR.

Expert Commentary

The Shift Toward ‘Aorta-First’

The current evidence base, strengthened by this nationwide IV analysis, supports a shift toward an ‘Aorta-First’ strategy. Experts suggest that for patients with stable CAD (excluding left main disease or high-grade proximal LAD lesions), the focus should be on successful valve replacement. If symptoms of angina persist post-TAVR, or if ischemia is demonstrated on non-invasive testing, PCI can be performed as a staged procedure.

Challenges of Post-TAVR Coronary Access

One caveat to the conservative approach is the technical difficulty of performing PCI after TAVR. Depending on the type of bioprosthesis used (e.g., self-expanding valves with high supra-annular frames), cannulating the coronary ostia can be challenging. Clinicians must weigh the ‘procedural insurance’ of pre-TAVR PCI against the ‘biological reality’ of increased bleeding. If a conservative approach is chosen, the choice of valve should ideally favor those that facilitate easy future coronary access.

Limitations and Controversies

While the IV analysis is robust, it cannot entirely replace a large-scale RCT. Critics point out that ‘significant CAD’ in these registries is often defined by visual angiographic assessment (≥50% stenosis), which may not always correlate with functional ischemia. Future research should focus on the utility of fractional flow reserve (FFR) or instantaneous wave-free ratio (iFR) in the TAVR population, as physiological assessment might better identify the subset of patients who truly benefit from revascularization.

Conclusion

In conclusion, routine PCI before TAVR in patients with significant CAD does not improve survival or reduce major ischemic events but significantly increases the risk of bleeding complications. While it reduces the need for subsequent non-urgent revascularization, the clinical value of this reduction is questionable given the lack of impact on mortality. Management should move away from a ‘routine revascularization’ mindset toward an individualized approach that prioritizes the relief of aortic stenosis and carefully assesses the bleeding-ischemic balance. Future guidelines will likely reflect this more conservative, patient-centered paradigm.

References

• Louca A, Petursson P, Sundström J, et al. PCI Versus Conservative Management Before TAVR in Patients With Significant Coronary Artery Disease: A Nationwide Instrumental Variable Analysis. Circ Cardiovasc Interv. 2026 Feb 20:e016337. PMID: 41717702.
• Patterson T, Clayton T, Dodd M, et al. ACTIVATION Trial Investigators. PCI in Patients Undergoing Transcatheter Aortic Valve Implantation. JACC Cardiovasc Interv. 2021;14(18):1965-1974. PMID: 34503310.
• Faroux L, Guimaraes L, Wintzer-Wehekind J, et al. Coronary Artery Disease and Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2019;74(3):362-372. PMID: 31319962.